The Alzheimer’s Drug Discovery Foundation (ADDF) announced yesterday the launch of its newly expanded ADDF ACCESS program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases. Through the effective selection of CROs and use of their services, researchers may be able to accelerate their research and bring novel therapies to patients faster.
Why Run? To raise awareness and money for the Alzheimer’s Drug Discovery Foundation.
What for? To honor his father, New York Giants Running Back, Ron Johnson, diagnosed in 2008 with early-onset Alzheimer’s disease…
New York N.Y. October 24th, 2013. This is one story of a runner with a reason. Thirty-one year old Chris Johnson, son of legendary New York Giants Running Back, Ron Johnson has taken up the cause to find the prevention, treatment and ultimately cure for a disease that once upon a time was as mysterious and taboo as cancer used to be. Why?
Partnership increases critical support for researchers’ efforts to find new therapies to treat Alzheimer’s disease
October 24, Cleveland, Ohio - The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals (UH) Case Medical Center announced today a newly formed partnership that will leverage their combined expertise and resources to advance highly promising Alzheimer’s disease drug discovery projects conducted in academic medical institutions nationwide.
The Alzheimer’s Drug Discovery Foundation (ADDF) presents its annual fall conference, the 14th International Conference on Alzheimer’s Drug Discovery taking place on September 9-10, 2013 at the Hyatt Regency in Jersey City, NJ, across the Hudson River from New York City.
Dr. Fillit and Dr. Emanuel present at the 2013 Aspen Ideas Festival, in a session titled, "Hope on the Horizon: New Strategies for the Preventions and Treatment of Alzheimer's Disease."
Earlier this month, the Centers for Medicare and Medicaid Services (CMS) issued a draft Decision Memorandum to deny Medicare reimbursements to patients using an innovative FDA-approved Alzheimer's diagnostic technology designed to help physicians identify whether patients with signs of cognitive impairment may have Alzheimer's or are in fact suffering from another form of dementia. This information is vital to patients, their providers, choices regarding their treatment and their ultimate health outcomes.
The Alzheimer's Drug Discovery Foundation (ADDF) today launched the ADDF ACCESS program to give the academic and small biotechnology communities online access to a marketplace of contract research organizations (CROs) and the industry standard preclinical drug discovery and development services they provide. Additionally, ADDF ACCESS offers educational resources and a network of expert consultants and collaborators who focus on drug discovery for diseases of the central nervous system (CNS) (http://www.alzdiscovery.org/research-and-grants/addf-access/).
The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer’s disease.
Re “Dementia Study Predicts a Surge in Cost and Cases” (front page, April 4):
The projected costs of dementia care are staggering, but this has been known for decades. It’s time we paid more attention to one of the fastest-growing chronic diseases in our country.